These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3301245)

  • 21. Anti-ulcer therapy. Past to present.
    Bettarello A
    Dig Dis Sci; 1985 Nov; 30(11 Suppl):36S-42S. PubMed ID: 2865091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of sucralfate in the prevention of recurrence of peptic ulcer--double blind multicenter study with cimetidine.
    Takemoto T; Kimura K; Okita K; Tsuneoka K; Ohshiba S; Namiki M; Fukuchi S; Miyake T; Fukutomi H; Okazaki Y
    Scand J Gastroenterol Suppl; 1987; 140():49-60. PubMed ID: 3328285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of sucralfate in peptic disease.
    Jensen SL; Funch Jensen P
    Dig Dis; 1992; 10(3):153-61. PubMed ID: 1611711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptic ulcers in the elderly: unique features and management.
    Freston MS; Freston JW
    Geriatrics; 1990 Jan; 45(1):39-42, 45. PubMed ID: 2403956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New ulcer drugs: is cimetidine out of date?].
    Fimmel CJ; Sabbatini F; Pace F; Caradonna P; Blum AL
    Ther Umsch; 1982 Nov; 39(11):841-51. PubMed ID: 6294895
    [No Abstract]   [Full Text] [Related]  

  • 26. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse rates following initial ulcer healing with sucralfate and cimetidine.
    Marks IN; Wright JP; Lucke W; Girdwood AH
    Scand J Gastroenterol Suppl; 1983; 83():53-6. PubMed ID: 6579632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Innovations in the treatment of gastroduodenal ulcers].
    Bernier JJ
    Presse Med; 1983 May; 12(21):1355-8. PubMed ID: 6304676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease.
    May B
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():113-6. PubMed ID: 2657280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current trends in the pharmacotherapy for peptic ulcer disease.
    Hixson LJ; Kelley CL; Jones WN; Tuohy CD
    Arch Intern Med; 1992 Apr; 152(4):726-32. PubMed ID: 1558429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of sucralfate and cimetidine in the treatment of duodenal and gastric ulcers. A multicenter study.
    Pop P; Nikkels RE; Thys O; Dorrestein GC
    Scand J Gastroenterol Suppl; 1983; 83():43-7. PubMed ID: 6356320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long term management of peptic ulcer. Indications and side effects of drug therapy compared with surgical procedure].
    Rösch W
    Fortschr Med; 1984 Jul; 102(25-26):688-91. PubMed ID: 6088375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs for treatment of peptic ulcers.
    Dajani EZ; Trotman BW
    J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients.
    Santander C; Grávalos RG; Gómez-Cedenilla A; Cantero J; Pajares JM
    Am J Gastroenterol; 1996 Aug; 91(8):1549-52. PubMed ID: 8759659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prevention of ulcer disease].
    Loizeau E
    Schweiz Med Wochenschr; 1986 Oct; 116(40):1371-4. PubMed ID: 2877491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study.
    Wong BC; Lam SK; Lai KC; Hu WH; Ching CK; Ho J; Yuen ST; Chan CK; Lau GK; Lai CL
    Aliment Pharmacol Ther; 1999 Mar; 13(3):303-9. PubMed ID: 10102962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.